Dianna Quan, MD

Professional Titles

• Director, Electromyography Laboratory
• Director, Neuromuscular Medicine Fellowship

Recognitions

• Regional Top Doctor, Castle Connolly (2013)
  Awarded to physicians in the mountain West for clinical excellence 2013-2022
• Top Doc, 5280 (2023)
  Clinical excellence award given to greater metropolitan Denver physicians by their peers

Publications

• Oskarsson B, Quan D, Rollins YR, Neville HE, Ringel SP, Arciniegas. Using the frontal assessment battery to identify executive function impairments in amyotrophic lateral sclerosis: a preliminary experience. Amyotrophic Lateral Sclerosis 2010;11:244-7.
• Levi ME, Quan D, Ho JT, Kleinschmidt-DeMasters BK, Tyler KL, Grazia TJ. Impact of Rituximab-associated B-cell Defects on West Nile Virus Meningoencephalitis in Solid Organ Transplant Recipients. Clin Transplantion 2010;24:223-8.
• Goldenholz DM, Oskarsson BE, Quan D, Wiley RG. Paraneoplastic Autonomic Neuropathy. eMedicine from WebMD. Updated December 10, 2010. Available at: http://emedicine.medscape.com/article/1156808-overview.
• Quan D. Muscular dystrophies and neurologic diseases that present as myopathy. Rheum Dis Clin N Am (in press).
• Quan D, Ringel SP. “Neuromuscular Diseases.” In: Weiner WJ, Goetz CG, and Shin RK, eds., Neurology for the Non Neurologist, 6th edition. Philadelphia: Lippincott Williams & Wilkins (in press).
• Quan D. Muscular dystrophies and neurologic diseases that present as myopathy. Rheum Dis Clin N Am 2011;37:233-244.
• Nordon-Craft A, Schenkman M, Quan D, Moss M. ICU acquired weakness. Physical Therapy (in press)
• Conceicao I, Coelho T, Plante-Bordeneuve V, Waddington-Cruz M, Ericzon BG, Falk R, Ikeda SI, Mauer M, Suhr, OB, Ando Y, Mazzeo A, Grogan D. Baseline neurologic function in symptomatic patients in the transtyretin amyloidosis outcomes survey (THAOS) (Dr. Quan is a member of the THAOS research group). Neurology 2011;76 (suppl 4):A111. Poster presented at the American Academy of Neurology, Honolulu, HI, April 9-16, 2011
• Wang A, Donkervoort S, Quan D, Mozaffar T, Kimonis V. ALS in a patient with VCP associated inclusion body myopathy. Neurology 2011;76 (suppl 4):A516. Poster presented at the American Academy of Neurology, Honolulu, HI, April 9-16, 2011
• Macht M, Quan D, Clark B, Benson A, Burnham E, Moss M. Development of an Efficient Screening Test for Critical Illness Polyneuropathy (CIP). Poster presented at the American Thoracic Society, Denver, CO, May 2011
• Graham A, Slavov D, Taylor M, Quan D. Clinical and genetic characterization of a kindred with Thr60Ala transthyretin familial amyloid polyneuropathy. Accepted for American Academy of Neurology meeting, New Orleans, LA, 2012
• Guillain-Barre Syndrome after West Nile Infection: A Case Report accepted for a poster presentation at the American Academy of Neurology 65th Annual Meeting, March 16 to March 23, 2013 at the San Diego
• Quan D. Varicella zoster virus and postherpetic neuralgia: A new era? Rochester, MN: American Association of Neuromuscular and Electrodiagnostic Medicine, 2012.
• Quan D, Arnold WD, DeSousa E. Neuromuscular vignettes. Rochester, MN: American Association of Neuromuscular and Electrodiagnostic Medicine, 2012.
• Nordon-Craft A, Schenkman M, Quan D, Moss M. ICU acquired weakness. Physical Therapy 2012;92:1-13.
• Development of on-line curriculum for neuromuscular fellows
• Development of neuromuscular pre and post tests for neurology resident neuromuscular elective rotation
• Quan D. “Electromyography and nerve conduction studies.” In: West S, ed., Rheumatology Secrets, 3rd edition. Philadelphia: Elsevier (in press).
• Quan D. “Neurology in the ICU.” In: Chan ED, Terada LS, Kortbeek JB Winston BW, eds., Bedside Critical Care Manual, 3e. Philadelphia: Hanley & Belfus (in press)
• Moss M, Yang M, Macht M, Sottile P, Gray L, McNulty M, Quan D. Screening for critical illness polyneuromyopathy with single nerve conduction studies. Intensive Care Med. 2014 Mar 13. [Epub ahead of print] PubMed PMID: 24623137
• Quan D. Median entrapment neuropathies. Rochester, MN: American Association of Neuromuscular and Electrodiagnostic Medicine, 2013.
• Mitsumoto H, Factor-Litvak P, Andrews H, et al. for the ALS COSMOS Study Group (Quan D collaborator). ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): study methodology, recruitment, and baseline demographic and disease characteristics. Amyotroph Lateral Scler Frontotemporal Degener 2014;15:192-203.
• Moss M, Yang M, Macht M, Sottile P, Gray L, McNulty M, Quan D. Screening for critical illness polyneuromyopathy with single nerve conduction studies.” Intensive Care Medicine 2014;40:683-90.
• Peltier A, Quan D. Neuromuscular vignettes. Rochester, MN: American Association of Neuromuscular and Electrodiagnostic Medicine, 2014.
• Quan D. “Electromyography and nerve conduction studies.” In: West S, ed., Rheumatology Secrets, 3rd edition. Philadelphia: Elsevier, 2014, pp. 78-81.
• Lin HC, Quan D. Diabetic Neuropathy. Medscape Reference. Updated April 10, 2014. Available at: http://emedicine.medscape.com/article/1170337-overview.
• Goldenholz DM, Oskarsson BE, Quan D, Wiley RG. Paraneoplastic Autonomic Neuropathy. Medscape Reference. Updated December 23, 2014. Available at: http://emedicine.medscape.com/article/1156808-overview
• Quan D. “Neurology in the ICU.” In: Chan ED, Terada LS, Kortbeek JB Winston BW, eds., Bedside Critical Care Manual, 3e. Philadelphia: Hanley & Belfus (in press).
• Quan D, Gray L, McNulty M, Yang M, Moss M. Increased compound motor action potential duration in critical illness myopathy. Poster presented at the American Thoracic Society meeting, San Diego, CA, April 2014.
• Sottile PD, Quan D, McNulty M, Gray L, Higgins C, Moss M. Outcomes in critical illness polyneuropathy and myopathy compared with deconditioning and normal neuromuscular function. Poster presented at the American Thoracic Society meeting, San Diego, CA, April 2014.
• Lozowska D, Liewluck T, Quan D, Ringel S. Exertional rhabdomyolysis associated with high intensity exercise. Muscle & Nerve 52:1134-1135, 2015.
• Quan D. “Electromyography and nerve conduction studies.” In: West S, ed., Rheumatology Secrets, 3rd edition. Philadelphia: Elsevier (in press).
• Quan D. “Neurology in the ICU.” In: Chan ED, Terada LS, Kortbeek JB Winston BW, eds., Bedside Critical Care Manual, 3e. Philadelphia: Hanley & Belfus (in press).
• Reynolds W, West M, Cerdan-Trevino M, Quan D, Tyler K. Guillain-Barre Syndrome after West Nile infection: A case report. Poster presented at the American Academy of Neurology, San Diego, CA, March 2013.
• Quan D, Gray L, McNulty M, Yang M, Moss M. Increased compound motor action potential duration in critical illness myopathy. Accepted for presentation to the American Thoracic Society meeting, 2014.
• Gurme M, Quan D, Oskarsson BE. Idiopathic orthostatic hypotension and other autonomic failure syndromes. Medscape Drugs & Diseases. Updated Nov. 19, 2015. Available at: http://emedicine.medscape.com/article/1154266-overview.
• Fleming J, Quan D. A case of congenital spinal muscular atrophy with pain due to a mutation in TRPV4. Neuromuscul Disord. 2016 Sep 16. [Epub ahead of print] PubMed PMID: 27751652
• Kelmenson DA, Quan D, Nordon-Craft A, Malone D, Schenkman M, Moss M. Electrophysiological abnormalities can differentiate pre-hospital discharge functional status in critically ill patients with normal strength. Intensive Care Med. 2016 Sep;42(9):1504-5. PubMed PMID: 27334267
• Quan D. Improving education in neuromuscular medicine-The essential ingredients. US Neurology 2016; 12:27-8
• Quan D. Lin HC. Diabetic Neuropathy. Medscape reference. Updated July 6, 216. Available at http://emedicine.medscape.com/article/1170337-overview
• Quan D. "Neurology in the ICU." In: Chan ED, Terada LS, Kortbeek JB, Winston BW, eds., Bedside Critical Care Manual, e3. Philadelphia: Hanley & Belfus (in press)
• Gurme M, Quan D, Oskarsson BE. Idiopathic orthostatic hypotension and other autonomic failure syndromes. Medscape Drugs & Diseases. Updated July 15, 2016. Available at: http://emedicine.medscape.com/article/1154266-overview.
• Kelmenson DA, Held N, Allen RR, Quan D, Burnham EL, Clark BJ, Ho PM, Kiser TH, Vandivier RW, Moss M. Outcomes of ICU Patients With a Discharge Diagnosis of Critical Illness Polyneuromyopathy: A Propensity-Matched Analysis. Crit Care Med. 2017 Oct 10. [Epub ahead of print] PubMed PMID: 29019851
• Kelmenson DA, Held N, Allen RR, Quan D, Burnham EL, Clark BJ, Ho PM, Kiser TH, Vandivier RW, Moss M. The authors reply. Crit Care Med. 2018 Apr;46(4):e347-e348. PubMed PMID: 29538131
• Quan D, Lin HC. Diabetic Neuropathy. Medscape Reference. Updated March 7, 2018. Available at: http://emedicine.medscape.com/article/1170337-overview
• Dixon S, Quan D. “Electromyography and nerve conduction studies.” In: Kolfenbach, ed., Rheumatology Secrets, 4rd edition. Philadelphia: Elsevier (in press).
• Barohn RJ, Gajewski B, Pasnoor M, Brown L, Herbelin L, Kimminau K, Jawdat O, Parks C, Shlemon P, Dimachkie MM, and the PAIN-CONTRoLs Study Team. Patient assisted intervention for neuropathy: comparison of treatment in real life situations (PAIN-CONTRoLS). Presented at the American Academy of Neurology, Los Angeles, CA, April 2018.
• Kelmenson D, Quan D, Moss M. Critical illness polyneuromyopathy in neurosurgical patients. Presented at the American Thoracic Society, San Diego, May 2018.
• Nowak RJ, Coffey C, Goldstein JM, Dimachkie M, Benatar M, Huq M, Pearson M, Yankey JW, Uribe L, Herbelin L, Burns TM, O'Connor KC, Conwit R, Kissel JT, Wolfe GI, Hafler DA, Cudkowicz ME, Barohn RJ, and NeuroNEXT NN103 BeatMG Study Team. B cell targeted treatment in myasthenia gravis (BeatMG)- A phase 2 trial of rituximab in MG: Topline results. Presented at the 15th International Congress on Neuromuscular Diseases, Vienna, Austria, July 2018.
• Ajroud-Driss S, Adams D, Coelho T, Polydefkis M, Gonzalez-Duarte A, Quan D, Kristen A, Berk JL, Partisano AM, Gollob J, Sweester M, Chen J, Argarwal S, Suhr OB. Impact of patisiran on overall health status in hATTR amyloidosis: Results from the APOLLO trial. Presented at the Peripheral Nerve Society, Baltimore, MD, July 2018.
• Polydefkis M, AdamsD , Kristen A, Gonzalez-Duarte A, Coelho T, Berk JL, Quan D, Partisano AM, Sweester M, Chen J, Gollob J, Suhr OB. Infusion related reactions in patients with hATTR amyloidosis treated with patisiran. Presented at the Peripheral Nerve Society, Baltimore, MD, July 2018.
• Quan D., Adams D., Gonzalez-Duarte A., Polydefkis M., Kristen A., Tournev I, Schmidt H., Coelho T., Berk J., Gandhi P.J.,Sweetser M., Lin T., Gollob J., Suhr O.B. Evaluating the Impact of Patisiran on Disability using the Rasch-built Overall Disability Scale (R-ODS) in Patients with Herediatary Transthyretin-Mediated (hATTR) Amyloidosis in the APOLLO Study. Presented at the American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting, Washington D.C., October 2018.
• Dixon S, Quan D. “Electromyography and nerve conduction studies.” In: Kolfenbach, ed., Rheumatology Secrets, 4rd edition. Philadelphia: Elsevier (in press).
• Aburahma SK, Wicklund MP, Quan D. Take two: Utility of the repeat skeletal muscle biopsy. Muscle Nerve. 2019 Jul;60(1):41-46. PubMed PMID: 30972775
• Shefner JM, Cudkowicz ME, Hardiman O, Cockcroft BM, Lee JH, Malik FI, Meng L, Rudnicki SA, Wolff AA, Andrews JA. A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2019;0(0):1-11. PubMed PMID: 31081694
• González-Duarte A, Berk JL, Quan D, Mauermann ML, Schmidt HH, Polydefkis M, Waddington-Cruz M, Ueda M, Conceição IM, Kristen AV, Coelho T, Cauquil CA, Tard C, Merkel M, Aldinc E, Chen J, Sweetser MT, Wang JJ, Adams D. Analysis of autonomic outcomes in APOLLO, a phase III trial of RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. Journal of Neurology. In press.
• Ajroud-Driss S, Adams D, Coelho T, Polydefkis M, González-Duarte A, Quan D, Kristen A, Berk JL, Partisano AM, Gollob J, Sweester M, Chen J, Agarwal S, Suhr OB. Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial. Presented at the American Academy of Neurology, Philadelphia, PA, May 2019.
• Mauricio E, González-Duarte A, Conceição I, Brannagan TH, Quan D, Mezei M, Schmidt H, Wixner J, Dinh Q, Berber E, Sweetser MT, White MT, Wang JJ, Ueda M. Autonomic manifestations of hereditary transthyretin-mediated amyloidosis: long-term safety and efficacy from the patisiran global open-label extension study. Presented at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM). Austin, TX, October 2019.
• Damy T, Kristen AV, Suhr OB, Maurer MS, Planté-Bordeneuve V, Yu CR, Ong ML, Coelho T, Rapezzi C, THAOS Investigators. Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS). Eur Heart J 2019 [Epub ahead of print].
• Adams D, Polydefkis M, González-Duarte A, Wixner J, Kristen AV, Schmidt HH, Berk JL, Losada López IA, Dispenzieri A, Quan D, Conceição IM, Slama MS, Gillmore JD, Kyriakides T, Ajroud-Driss S, Waddington-Cruz M, Mezei MM, Planté-Bordeneuve V, Attarian S, Mauricio E, Brannagan TH, Ueda M, Aldinc E, Wang JJ, White MT, Vest J, Berber E, Sweetser MT, Coelho T, on behalf of the patisiran Global OLE study group. Long-term efficacy and safety of patisiran in patients with hereditary transthyretin amyloidosis with polyneuropathy: Interim 1-year results from an open-label extension study. Lancet Neurology (accepted Sept. 21, 2020).
• Shefner JM, Andrews JA, Genge A, Jackson C, Lechtzin N, Miller TM, Cockroft BM, Meng L, Wei J, Wolff AA, Malik FI, Bodkin C, Brooks BR, Caress J, Dionne A, Fee D, Goutman SA, Goyal NA, Hardiman O, Hayat G, Heiman-Patterson T, Heitzman D, Henderson RD, Johnston W, Karam C, Kiernan MC, Kolb SJ, Korngut L, Ladha S, Matte G, Mora JS, Needham M, Oskarsson B, Pattee GL, Pioro EP, Pulley M, Quan D, Rezania K, Schellenberg KL, Schultz D, Shoesmith C, Simmons Z, Statland J, Sultan S, Swenson A, Berg LHVD, Vu T, Vucic S, Weiss M, Whyte-Rayson A, Wymer J, Zinman L, Rudnicki SA. A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2020 Sep 24;:1-13. [Epub ahead of print] PubMed PMID: 32969758
• Barohn RJ, Gajewski B, Pasnoor M, Brown A, Herbelin LL, Kimminau KS, Mudaranthakam DP, Jawdat O, Dimachkie MM, Iyadurai S, Stino A, Kissel J, Pascuzzi R, Brannagan T, Wicklund M, Ahmed A, Walk D, Smith G, Quan D, Heitzman D, Tobon A, Ladha S, Wolfe G, Pulley M, Hayat G, Li Y, Thaisetthawatkul P, Lewis R, Biliciler S, Sharma K, Salajegheh K, Trivedi J, Mallonee W, Burns T, Jacoby M, Bril V, Vu T, Ramchandren S, Bazant M, Austin S, Karam C, Hussain Y, Kutz C, Twydell P, Scelsa S, Kushlaf H, Wymer J, Hehir M, Kolb N, Ralph J, Barboi A, Verma N, Ahmed M, Memon A, Saperstein D, Lou JS, Swenson A, Cash T. Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS): Bayesian Adaptive Comparative Effectiveness Randomized Trial. JAMA Neurol. 2020 Aug 17. [Epub ahead of print] PubMed PMID: 32809014
• González-Duarte A, Berk JL, Quan D, Mauermann ML, Schmidt HH, Polydefkis M, Waddington-Cruz M, Ueda M, Conceição IM, Kristen AV, Coelho T, Cauquil CA, Tard C, Merkel M, Aldinc E, Chen J, Sweetser MT, Wang JJ, Adams D. Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. J Neurol. 2020 Mar;267(3):703-712. PubMed PMID: 31728713
• Guptill J, Antozzi C, Bril V, Gamez J, Meuth S, Munoz Blanco JL, Nowak R, Quan D, Sevilla T, Szczudlik A, Hegarty B, Jouvin MH, Jin J, Arroyo S. Vivacity-MG: A phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of nipocalimab administered to adults with generalized myasthenia gravis. Poster presented at the American Association of Neuromuscular and Electrodiagnostic Medicine, Virtual Meeting, October 2020.
• Quan D, Dixon S. “Electromyography and nerve conduction studies.” In: West and Kolfenbach, eds., Rheumatology Secrets, 4rd edition. Philadelphia: Elsevier 2020, pp. 85-88
• Stevens D, Quan D. “Diabetic Neuropathies.” In: McDermott, ed., Diabetes Secrets. Philadelphia: Elsevier (in press).
• Kennedy A, Kaplan J, Quan D. A 40-Year-Old Man With Dizziness, Confusion, and Neuropathy 2020, https://reference.medscape.com/viewarticle/923933
• Adams D, Polydefkis M, González-Duarte A, Wixner J, Kristen AV, Schmidt HH, Berk JL, Losada López IA, Dispenzieri A, Quan D, Conceição IM, Slama MS, Gillmore JD, Kyriakides T, Ajroud-Driss S, Waddington-Cruz M, Mezei MM, Planté-Bordeneuve V, Attarian S, Mauricio E, Brannagan TH 3rd, Ueda M, Aldinc E, Wang JJ, White MT, Vest J, Berber E, Sweetser MT, Coelho T. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Lancet Neurol. 2021 Jan;20(1):49-59. PubMed PMID: 33212063
• Shefner JM, Andrews JA, Genge A, Jackson C, Lechtzin N, Miller TM, Cockroft BM, Meng L, Wei J, Wolff AA, Malik FI, Bodkin C, Brooks BR, Caress J, Dionne A, Fee D, Goutman SA, Goyal NA, Hardiman O, Hayat G, Heiman-Patterson T, Heitzman D, Henderson RD, Johnston W, Karam C, Kiernan MC, Kolb SJ, Korngut L, Ladha S, Matte G, Mora JS, Needham M, Oskarsson B, Pattee GL, Pioro EP, Pulley M, Quan D, Rezania K, Schellenberg KL, Schultz D, Shoesmith C, Simmons Z, Statland J, Sultan S, Swenson A, Berg LHVD, Vu T, Vucic S, Weiss M, Whyte-Rayson A, Wymer J, Zinman L, Rudnicki SA. A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2021 May;22(3-4):287-299. PubMed PMID: 32969758
• Caponetti AG, Rapezzi C, Gagliardi C, Milandri A, Dispenzieri A, Kristen AV, Wixner J, Maurer MS, Garcia-Pavia P, Tournev I, Planté-Bordeneuve V, Chapman D, Amass L. Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis: Insights From THAOS. JACC Heart Fail. 2021 Oct;9(10):736-746. PubMed PMID: 34391735
• Kang X, Quan D. Electrodiagnostic Assessment of Motor Neuron Disease. Neurol Clin. 2021 Nov;39(4):1071-1081. PubMed PMID: 34602215
• Barroso FA, Coelho T, Dispenzieri A, Conceição I, Waddington-Cruz M, Wixner J, Maurer MS, Rapezzi C, Planté-Bordeneuve V, Kristen AV, González-Duarte A, Chapman D, Stewart M, Amass L; THAOS investigators. Characteristics of patients with autonomic dysfunction in the Transthyretin Amyloidosis Outcomes Survey (THAOS). Amyloid. 2022 Sep;29(3):175-183. doi: 10.1080/13506129.2022.2043270. Epub 2022 Apr 22. PMID: 35451899.
• Coelho T, Conceição I, Waddington-Cruz M, Keohane D, Sultan MB, Chapman D, Amass L; THAOS investigators. A natural history analysis of asymptomatic TTR gene carriers as they develop symptomatic transthyretin amyloidosis in the Transthyretin Amyloidosis Outcomes Survey (THAOS). Amyloid. 2022 Jun 22:1-9. doi: 10.1080/13506129.2022.2070470. Epub ahead of print. PMID: 35730447.
• Nowak RJ, Coffey CS, Goldstein JM, Dimachkie MM, Benatar M, Kissel JT, Wolfe GI, Burns TM, Freimer ML, Nations S, Granit V, Smith AG, Richman DP, Ciafaloni E, Al-Lozi MT, Sams LA, Quan D, Ubogu E, Pearson B, Sharma A, Yankey JW, Uribe L, Shy M, Amato AA, Conwit R, O'Connor KC, Hafler DA, Cudkowicz ME, Barohn RJ; NeuroNEXT NN103 BeatMG Study Team. Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study. Neurology. 2021 Dec 2;98(4):e376–89. doi: 10.1212/WNL.0000000000013121. Epub ahead of print. PMID: 34857535; PMCID: PMC8793103.
• Dispenzieri A, Coelho T, Conceição I, Waddington-Cruz M, Wixner J, Kristen AV, Rapezzi C, Planté-Bordeneuve V, Gonzalez-Moreno J, Maurer MS, Grogan M, Chapman D, Amass L; THAOS investigators. Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update. Orphanet J Rare Dis. 2022 Jun 18;17(1):236. doi: 10.1186/s13023-022-02359-w. PMID: 35717381; PMCID: PMC9206752.
• Adams D, Tournev IL, Taylor MS, Coelho T, Planté-Bordeneuve V, Berk JL, González-Duarte A, Gillmore JD, Low SC, Sekijima Y, Obici L, Chen C, Badri P, Arum SM, Vest J, Polydefkis M; HELIOS-A Collaborators. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid. 2022 Jul 23:1-9. doi: 10.1080/13506129.2022.2091985. Epub ahead of print. PMID: 35875890.
• Quan D, Obici L, Berk JL, Ando Y, Aldinc E, White MT, Adams D. Impact of baseline polyneuropathy severity on patisiran treatment outcomes in the APOLLO trial. Amyloid. 2022 Sep 18;:1-10. [Epub ahead of print] PubMed PMID: 36120830
• Stevens D, Quan D. “Diabetic neuropathies.” In: McDermott and Trujillo, eds., Diabetes Secrets, 1st edition. Philadelphia: Elsevier 2022
• Caponetti AG, Rapezzi C, Gagliardi C, Milandri A, Dispenzieri A, Kristen AV, Wixner J, Maurer MS, Garcia-Pavia P, Tournev I, Planté-Bordeneuve V, Chapman D, Amass L; THAOS Investigators. Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis: Insights From THAOS. JACC Heart Fail. 2021 Oct;9(10):736-746.
• Nativi-Nicolau J, Siu A, Dispenzieri A, Maurer MS, Rapezzi C, Kristen AV, Garcia-Pavia P, LoRusso S, Waddington-Cruz M, Lairez O, Witteles R, Chapman D, Amass L, Grogan M; THAOS Investigators. Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey. JACC CardioOncol. 2021 Oct 19;3(4):537-546.
• Gentile L, Tournev I, Amass L, Chapman D, Mazzeo A; THAOS investigators. Phenotypic Differences of Glu89Gln Genotype in ATTR Amyloidosis From Endemic Loci: Update From THAOS. Cardiol Ther. 2021 Dec;10(2):481-490.
• Waddington-Cruz M, Wixner J, Amass L, Kiszko J, Chapman D, Ando Y; THAOS investigators. Characteristics of Patients with Late- vs. Early-Onset Val30Met Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey (THAOS). Neurol Ther. 2021 Dec;10(2):753-766.
• Kang X, Quan D. Electrodiagnostic Assessment of Motor Neuron Disease. Neurol Clin. 2021 Nov;39(4):1071-1081.
• Bhai SF, Brown A, Gajewski B, Kimminau KS, Waitman LR, Pasnoor M, Barohn RJ; PAIN-CONTRoLS Study Team. A secondary analysis of PAIN-CONTRoLS: Pain's impact on sleep, fatigue, and activities of daily living. Muscle Nerve. 2022 Oct;66(4):404-410.
• Jacoby E, Quan D, Todd E, Rafaels N, Smith H, Crooks K. Prevalence of pathogenic transthyretin gene variants in the Rocky Mountain West region. Accepted for presentation at the American Association of Neuromuscular and Electrodiagnostic Medicine. Phoenix, AZ, Nov 2023.
• Luigetti M, Quan D, BerkJL, Conceição I, Misumi Y, Chao CC, Bender S, Aldinc E, Vest J, Adams D. Impact of Baseline Polyneuropathy Severity on Vutrisiran Treatment Response in the Phase 3 HELIOS-A Study. Presented at the Peripheral Nerve Society, Copenhagen, Denmark, June 2023
• Sperry B, Quan D, Mauricio E, Small R, Ananthasubramaniam K, Egolum U, Roblin S, Yureneva E, Chou LN, Jay P, Capocell K, Freimer M. Effect of RNAi on cardiomyopathy and polyneuropathy outcomes in patients with V122I variant hereditary transthyretin-mediated (hATTR or ATTRv) amyloidosis. Presented at the American College of Cardiology, New Orleans, LA, March 2023.
• Quan D, Obici L, Berk JL, Ando Y, Aldinc E, White MT, Adams D. Impact of baseline polyneuropathy severity on patisiran treatment outcomes in the APOLLO trial. Amyloid. 2023 Mar;30(1):49-58. PubMed PMID: 36120830
• Antozzi C, Guptill J, Bril V, Gamez J, Meuth SG, Nowak RF, Quan D, Sevilla T, Jouvin MH, Jin J, Karcher K, Ramchandren S, Sun H, Ling L, Zhu YW, Arroyo S. Safety and Efficacy of Nipocalimab in Patients with Generalized Myasthenia Gravis: Results from the Randomized Phase 2 Vivacity-MG study. Neurology 2023 (in press).
• Mora-Ayestaran N, Dispenzieri A, Kristen AV, Maurer MS, Diemberger I, Drachman BM, Grogan M, Gupta P, Glass O, Amass L, Garcia-Pavia P. Age- and Sex-Related Differences in Patients With Wild-Type Transthyretin Amyloidosis: Insights From THAOS. JACC Adv. 2024 Aug;3(8):101086. PubMed PMID: 39105117
• Luigetti M, Quan D, Berk JL, Conceição I, Misumi Y, Chao CC, Bender S, Aldinc E, Vest J, Adams D. Impact of Baseline Neuropathy Severity on Vutrisiran Treatment Response in the Phase 3 HELIOS-A Study. Neurol Ther. 2024 Jun;13(3):625-639. PubMed PMID: 38512694
• Antozzi C, Guptill J, Bril V, Gamez J, Meuth SG, Nowak RJ, Quan D, Sevilla T, Jouvin MH, Jin J, Karcher K, Ramchandren S, Sun H, Ling L, Zhu Y, Arroyo S. Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis: Results From the Randomized Phase 2 Vivacity-MG Study. Neurology. 2024 Jan 23;102(2):e207937. PubMed PMID: 38165333
• González-Moreno J, Dispenzieri A, Grogan M, Coelho T, Tournev I, Waddington-Cruz M, Wixner J, Diemberger I, Garcia-Pavia P, Chapman D, Gupta P, Glass O, Amass L. Clinical and Genotype Characteristics and Symptom Migration in Patients With Mixed Phenotype Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey. Cardiol Ther. 2024 Mar;13(1):117-135. PubMed PMID: 38117424

Professional Memberships

• American Academy of Neurology, Fellow
• American Association of Neuromuscular & Electrodiagnostic Medicine, Fellow
• Colorado Society of Clinical Neurologists, Member
• American Neurological Association, Fellow

Practice Locations

UCHealth Neurosciences Center - Anschutz Medical Campus
1635 Aurora Ct
4th Floor
Aurora, CO 80045
720-848-2080

UCHealth Anschutz Outpatient Pavilion - Anschutz Medical Campus
1635 Aurora Ct
Aurora, CO 80045
720-848-0000

Hospital Affiliation

• University of Colorado Hospital

Specialty Information

Specialties

• Neurology, Board Certification
• Neuromuscular Medicine, Board Certification
• American Board of Electrodiagnostic Medicine, Board Certification (0001)

Conditions & Treatments

• Brain and Nervous System - Neuromuscular Diseases
• Brain and Nervous System